Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01754935 · ClinicalTrials.gov registry record · Phase 2

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

A Phase 2 study of Rheumatoid Arthritis, sponsored by Vertex Pharmaceuticals Incorporated.

Completed
Registry status
Phase 2
Development phase
43
Enrollment target
20
Study locations

NCT01754935 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 43 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01754935, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Vertex Pharmaceuticals Incorporated.

COMPLETED
Registry status
Phase 2
Development phase
43 participants
Enrollment target
20
Study locations

Study Summary

The current study is designed to evaluate the safety and efficacy, including MRI imaging, across a range of VX-509 doses in subjects with active rheumatoid arthritis (RA) who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs).

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG VX-509
  • DRUG VX-509 matching placebo

Study Locations (20)

Florida

  • Vertex Investigational Site - Fort Lauderdale
  • Vertex Investigational Site - Venice
  • Vertex Investigational Site - West Palm Beach

Texas

  • Vertex Investigational Site - Katy
  • Vertex Investigational Site - San Antonio
  • Vertex Investigational Site - Webster

California

  • Vertex Investigational Site - Stanford
  • Vertex Investigational Site - Upland

Georgia

  • Vertex Investigational Site - Canton
  • Vertex Investigational Site - Decatur

Kansas

  • Vertex Investigational Site - Kansas City

Kentucky

  • Vertex Investigational Site - Elizabethtown

Maryland

  • Vertex Investigational Site - Frederick

Nebraska

  • Vertex Investigational Site - Lincoln

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2013-01
Est. Completion 2014-02
Phase Phase 2

Sponsor

Vertex Pharmaceuticals Incorporated

191 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01754935

The ClinicalTrials.gov registry entry for NCT01754935 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which VX-509 is the first listed.

NCT01754935 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Texas, California.

Frequently Asked Questions

What is clinical trial NCT01754935 about?

NCT01754935 is a clinical study titled "A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor". The current study is designed to evaluate the safety and efficacy, including MRI imaging, across a range of VX-509 doses in subjects with active rheumatoid arthritis (RA) who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs).

What is the current status of trial NCT01754935?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2013-01. Estimated completion is 2014-02.

What conditions does trial NCT01754935 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT01754935?

The interventions under investigation include: VX-509 (DRUG), VX-509 matching placebo (DRUG).

Who is sponsoring clinical trial NCT01754935?

This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01754935 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.